Cargando…

Tropoelastin: an in vivo imaging marker of dysfunctional matrix turnover during abdominal aortic dilation

AIMS: Dysfunctional matrix turnover is present at sites of abdominal aortic aneurysm (AAA) and leads to the accumulation of monomeric tropoelastin rather than cross-linked elastin. We used a gadolinium-based tropoelastin-specific magnetic resonance contrast agent (Gd-TESMA) to test whether quantifyi...

Descripción completa

Detalles Bibliográficos
Autores principales: Lavin, Begoña, Lacerda, Sara, Andia, Marcelo E., Lorrio, Silvia, Bakewell, Robert, Smith, Alberto, Rashid, Imran, Botnar, René M., Phinikaridou, Alkystis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7104357/
https://www.ncbi.nlm.nih.gov/pubmed/31282949
http://dx.doi.org/10.1093/cvr/cvz178
_version_ 1783512220603252736
author Lavin, Begoña
Lacerda, Sara
Andia, Marcelo E.
Lorrio, Silvia
Bakewell, Robert
Smith, Alberto
Rashid, Imran
Botnar, René M.
Phinikaridou, Alkystis
author_facet Lavin, Begoña
Lacerda, Sara
Andia, Marcelo E.
Lorrio, Silvia
Bakewell, Robert
Smith, Alberto
Rashid, Imran
Botnar, René M.
Phinikaridou, Alkystis
author_sort Lavin, Begoña
collection PubMed
description AIMS: Dysfunctional matrix turnover is present at sites of abdominal aortic aneurysm (AAA) and leads to the accumulation of monomeric tropoelastin rather than cross-linked elastin. We used a gadolinium-based tropoelastin-specific magnetic resonance contrast agent (Gd-TESMA) to test whether quantifying regional tropoelastin turnover correlates with aortic expansion in a murine model. The binding of Gd-TESMA to excised human AAA was also assessed. METHODS AND RESULTS: We utilized the angiotensin II (Ang II)-infused apolipoprotein E gene knockout (ApoE(-/-)) murine model of aortic dilation and performed in vivo imaging of tropoelastin by administering Gd-TESMA followed by late gadolinium enhancement (LGE) magnetic resonance imaging (MRI) and T(1) mapping at 3 T, with subsequent ex vivo validation. In a cross-sectional study (n = 66; control = 11, infused = 55) we found that Gd-TESMA enhanced MRI was elevated and confined to dilated aortic segments (control: (LGE)=0.13 ± 0.04 mm(2), control (R1)= 1.1 ± 0.05 s(-1) vs. dilated (LGE)=1.0 ± 0.4 mm(2), dilated (R1) =2.4 ± 0.9 s(-1)) and was greater in segments with medium (8.0 ± 3.8 mm(3)) and large (10.4 ± 4.1 mm(3)) compared to small (3.6 ± 2.1 mm(3)) vessel volume. Furthermore, a proof-of-principle longitudinal study (n = 19) using Gd-TESMA enhanced MRI demonstrated a greater proportion of tropoelastin: elastin expression in dilating compared to non-dilating aortas, which correlated with the rate of aortic expansion. Treatment with pravastatin and aspirin (n = 10) did not reduce tropoelastin turnover (0.87 ± 0.3 mm(2) vs. 1.0 ± 0.44 mm(2)) or aortic dilation (4.86 ± 2.44 mm(3) vs. 4.0 ± 3.6 mm(3)). Importantly, Gd-TESMA-enhanced MRI identified accumulation of tropoelastin in excised human aneurysmal tissue (n = 4), which was confirmed histologically. CONCLUSION: Tropoelastin MRI identifies dysfunctional matrix remodelling that is specifically expressed in regions of aortic aneurysm or dissection and correlates with the development and rate of aortic expansion. Thus, it may provide an additive imaging marker to the serial assessment of luminal diameter for surveillance of patients at risk of or with established aortopathy.
format Online
Article
Text
id pubmed-7104357
institution National Center for Biotechnology Information
language English
publishDate 2019
record_format MEDLINE/PubMed
spelling pubmed-71043572020-04-01 Tropoelastin: an in vivo imaging marker of dysfunctional matrix turnover during abdominal aortic dilation Lavin, Begoña Lacerda, Sara Andia, Marcelo E. Lorrio, Silvia Bakewell, Robert Smith, Alberto Rashid, Imran Botnar, René M. Phinikaridou, Alkystis Cardiovasc Res Article AIMS: Dysfunctional matrix turnover is present at sites of abdominal aortic aneurysm (AAA) and leads to the accumulation of monomeric tropoelastin rather than cross-linked elastin. We used a gadolinium-based tropoelastin-specific magnetic resonance contrast agent (Gd-TESMA) to test whether quantifying regional tropoelastin turnover correlates with aortic expansion in a murine model. The binding of Gd-TESMA to excised human AAA was also assessed. METHODS AND RESULTS: We utilized the angiotensin II (Ang II)-infused apolipoprotein E gene knockout (ApoE(-/-)) murine model of aortic dilation and performed in vivo imaging of tropoelastin by administering Gd-TESMA followed by late gadolinium enhancement (LGE) magnetic resonance imaging (MRI) and T(1) mapping at 3 T, with subsequent ex vivo validation. In a cross-sectional study (n = 66; control = 11, infused = 55) we found that Gd-TESMA enhanced MRI was elevated and confined to dilated aortic segments (control: (LGE)=0.13 ± 0.04 mm(2), control (R1)= 1.1 ± 0.05 s(-1) vs. dilated (LGE)=1.0 ± 0.4 mm(2), dilated (R1) =2.4 ± 0.9 s(-1)) and was greater in segments with medium (8.0 ± 3.8 mm(3)) and large (10.4 ± 4.1 mm(3)) compared to small (3.6 ± 2.1 mm(3)) vessel volume. Furthermore, a proof-of-principle longitudinal study (n = 19) using Gd-TESMA enhanced MRI demonstrated a greater proportion of tropoelastin: elastin expression in dilating compared to non-dilating aortas, which correlated with the rate of aortic expansion. Treatment with pravastatin and aspirin (n = 10) did not reduce tropoelastin turnover (0.87 ± 0.3 mm(2) vs. 1.0 ± 0.44 mm(2)) or aortic dilation (4.86 ± 2.44 mm(3) vs. 4.0 ± 3.6 mm(3)). Importantly, Gd-TESMA-enhanced MRI identified accumulation of tropoelastin in excised human aneurysmal tissue (n = 4), which was confirmed histologically. CONCLUSION: Tropoelastin MRI identifies dysfunctional matrix remodelling that is specifically expressed in regions of aortic aneurysm or dissection and correlates with the development and rate of aortic expansion. Thus, it may provide an additive imaging marker to the serial assessment of luminal diameter for surveillance of patients at risk of or with established aortopathy. 2019-07-08 2019-07-08 /pmc/articles/PMC7104357/ /pubmed/31282949 http://dx.doi.org/10.1093/cvr/cvz178 Text en http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Article
Lavin, Begoña
Lacerda, Sara
Andia, Marcelo E.
Lorrio, Silvia
Bakewell, Robert
Smith, Alberto
Rashid, Imran
Botnar, René M.
Phinikaridou, Alkystis
Tropoelastin: an in vivo imaging marker of dysfunctional matrix turnover during abdominal aortic dilation
title Tropoelastin: an in vivo imaging marker of dysfunctional matrix turnover during abdominal aortic dilation
title_full Tropoelastin: an in vivo imaging marker of dysfunctional matrix turnover during abdominal aortic dilation
title_fullStr Tropoelastin: an in vivo imaging marker of dysfunctional matrix turnover during abdominal aortic dilation
title_full_unstemmed Tropoelastin: an in vivo imaging marker of dysfunctional matrix turnover during abdominal aortic dilation
title_short Tropoelastin: an in vivo imaging marker of dysfunctional matrix turnover during abdominal aortic dilation
title_sort tropoelastin: an in vivo imaging marker of dysfunctional matrix turnover during abdominal aortic dilation
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7104357/
https://www.ncbi.nlm.nih.gov/pubmed/31282949
http://dx.doi.org/10.1093/cvr/cvz178
work_keys_str_mv AT lavinbegona tropoelastinaninvivoimagingmarkerofdysfunctionalmatrixturnoverduringabdominalaorticdilation
AT lacerdasara tropoelastinaninvivoimagingmarkerofdysfunctionalmatrixturnoverduringabdominalaorticdilation
AT andiamarceloe tropoelastinaninvivoimagingmarkerofdysfunctionalmatrixturnoverduringabdominalaorticdilation
AT lorriosilvia tropoelastinaninvivoimagingmarkerofdysfunctionalmatrixturnoverduringabdominalaorticdilation
AT bakewellrobert tropoelastinaninvivoimagingmarkerofdysfunctionalmatrixturnoverduringabdominalaorticdilation
AT smithalberto tropoelastinaninvivoimagingmarkerofdysfunctionalmatrixturnoverduringabdominalaorticdilation
AT rashidimran tropoelastinaninvivoimagingmarkerofdysfunctionalmatrixturnoverduringabdominalaorticdilation
AT botnarrenem tropoelastinaninvivoimagingmarkerofdysfunctionalmatrixturnoverduringabdominalaorticdilation
AT phinikaridoualkystis tropoelastinaninvivoimagingmarkerofdysfunctionalmatrixturnoverduringabdominalaorticdilation